Hematological Agents : Anticoagulants
IAGGL1 “Agglutex injection” 5000 IU/ml; 10 ml/vial
IAGGL2 “Agglutex injection” 5000 IU/ml; 5 ml/vial
IHEPA6 “Hepac Lock Flush injection” 100 USP unit/ml; 10 ml/pre-filled syringe
[泡法]
25000 IU in N/S 500ml, loading 60IU/kg, maintain 12IU/kg/hr
[備註]
Keep APTT 50″-70″(Heparin 不影響INR)
>3x: 減少infusion rate 50%
2-3x: 減少infusion rate 25%
1.5-2x: no change
<1.5x: 增加infusion rate 25%
適應症：
IAGGL1, IAGGL2：血栓性栓塞症及其預防、抗凝血。
IHEPA6：用於維持血管通道裝置的暢通，不可用於抗凝血治療。
Usual dose:
Acute ST segment elevation myocardial infarction: 60 units/kg IV bolus (max. 4000 units) then 12 units/kg/h (max. 1000 units/h).
Acute coronary syndrome: 60-70 units/kg IV bolus (max. 5000 units) then 12-15 units/kg/h (max. 1000 units/h).
Venous thromboembolism: IV bolus, 80 units/kg then 18 units/kg/h.
Central venous catheter occlusion, prophylaxis: depends on type of device, generally inject a quantity of heparin 100 units/ml sufficient to fill the entire device (3-5 ml), replace the solution each time the device is used, institution specific protocols will vary.
Contraindication:
Aintravascular coagulation, severe thrombocytopenia.
Instances in which blood coagulation tests cannot be performed at necessary intervals.
Precaution:
Allergic or hypersensitivity-type reactions.
Adverse effect:
Common: erythema, injection site ulcer, after deep subcutaneous injection, hematoma, heparin-induced thrombocytopenia, pain, local irritation symptom.
Serious: hemorrhage, heparin-induced thrombocytopenia with thrombosis, delayed heparin-induced thrombocytopenia with thrombosis, increased liver aminotransferase level, anaphylaxis, immune hypersensitivity reaction, osteoporosis (with long-term, high-dose administration).